Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University Hospital Dubrava
Patients with glaucoma and pseudophakic bullous keratopathy will be randomly divided in two groups. Group 1 will take topical netarsudil/latanoprost 1x daily for 3 months and group 2 will take topical placebo (artificial tear substitute) 1x daily for 3 months. Visual acuity (VA) will be evaluated using Snellen chart and converted to logarithm of the minimum angle of resolution (LogMAR). Central corneal thickness (CCT) measurements will be performed using OCT (Optovue Ivue). Information about intraocular pressure and adverse effects will be recorded during the study. Patients will visit every two weeks for checkups and measurements for 12 weeks.
Age
40–90
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
both sex,
age between 40 and 90 years
pseudophakic bullous keratopathy
glaucoma
You may not be if
other anterior segment pathology (corneal opacities);
ocular surface inflammation
retinal diseases affecting visual acuity
current treatment with topical prostaglandin analogue
Clareo Health | The Effect of ROCK Inhibitors on Corneas of Patients With Glaucoma and Pseudophakic Bullous Keratopathy (PBK)
